Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes

Investigating the Impact of Immune-Related Adverse Events, Glucocorticoid Use and Immunotherapy Interruption on Long-Term Survival Outcomes

It remains unclear whether immune-related adverse events (irAEs) and glucocorticoid use could impact long-term outcomes in patients treated for solid tumors with immune checkpoint inhibitors (ICI). All patients treated with a single-agent ICI for any advanced cancer were included in this retrospecti...

Full description

Bibliographic Details
Main Authors: Charline Lafayolle de la Bruyère, Pierre-Jean Souquet, Stéphane Dalle, Pauline Corbaux, Amélie Boespflug, Michaël Duruisseaux, Lize Kiakouama-Maleka, Thibaut Reverdy, Madeleine Maugeais, Gulsum Sahin, Denis Maillet, Julien Péron
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cancers
Subjects:
immune-related adverse events
glucocorticoid use
ICI interruption
irAEs management
Online Access:https://www.mdpi.com/2072-6694/13/10/2365

Internet

https://www.mdpi.com/2072-6694/13/10/2365

Similar Items